Liver cells release the high mobility group box-1 (HMGB1) protein when exposed to lipopolysaccharides (LPSs). However, the timing and levels of protein released remain unclear. The present study aimed to characterize the secretion of the late pro-inflammatory cytokine HMGB1 by liver L02 and HepG2 cells. The human mononuclear macrophage cell line U937 was used as a control. Various concentrations of LPS were added to human U937, L02 and HepG2 cells for different durations, and the cells were analyzed at different time-points following this addition. Reverse transcription polymerase chain reaction (RT-PCR) was used to measure cellular HMGB1 mRNA levels, western blotting was performed to detect HMGB1 in cellular supernatants and the translocation of HMGB1 from the nucleus to the cytosol was examined using immunofluorescence staining. L02 and HepG2 cells exhibited higher HMGB1 mRNA levels compared with the control U937 cells 20 and 24 h following continuous exposure to LPS. U937 cells exhibited higher HMGB1 mRNA levels compared with the corresponding L02 and HepG2 cells 16 h following LPS exposure. The phase of HMGB1 protein detected in the cellular supernatants of L02 and HepG2 cells (16 h) was later than that of U937 cells (8 h). For the three cell lines, HMGB1 levels demonstrated a time dependency; however, the protein level was the highest in U937 cells. In the three cell lines, translocation of HMGB1 from the nucleus to the cytosol occurred; however, the phases of HMGB1 translocation in L02 and HepG2 cells occurred later than in U937 cells. LPS-induced secretion of the late pro‑inflammatory cytokine HMGB1 by liver cells is characterized by a late phase of release and smaller quantity, and the process of HMGB1 secretion appears to be associated with HMGB1 translocation.

Download full-text PDF

Source
http://dx.doi.org/10.3892/mmr.2013.1482DOI Listing

Publication Analysis

Top Keywords

l02 hepg2
28
hepg2 cells
28
hmgb1
15
cells
13
hmgb1 mrna
12
mrna levels
12
u937 cells
12
liver l02
8
liver cells
8
hmgb1 protein
8

Similar Publications

Simultaneous inhibition of two or more pathways is playing a crucial role in the treatment of hepatocellular carcinoma with complex and diverse pathogenesis. However, there have been no reports of dual-targeting inhibitors for protein kinase membrane-associated tyrosine/threonine 1 (PKMYT1) and histone deacetylase 2 (HDAC2), which are critical targets for hepatocellular carcinoma treatment. Here, an integrated strategy of virtual screening was utilized to identify dual-targeting inhibitors for PKMYT1 and HDAC2.

View Article and Find Full Text PDF

The escalating threat of antibiotic-resistant bacteria and fungi underscores an urgent need for new antimicrobial agents. This study aimed to synthesize and evaluate the antimicrobial activities of two series of 3-alkylidene-2-indolone derivatives. We synthesized 32 target compounds, among which 25 exhibited moderate to high antibacterial or antifungal activities.

View Article and Find Full Text PDF
Article Synopsis
  • Developing chemiluminescent (CL) probes that can effectively differentiate between liver tumors and healthy tissue is essential for better visualization during surgery.
  • A new CL probe, CYP-PD, was created to specifically target the enzyme CYP 2J2, which is found in high levels in liver tumors but not in healthy tissues.
  • CYP-PD showed impressive sensitivity, detecting as low as 1.21 pM of the enzyme and providing a high tumor-to-normal tissue ratio, making it a promising tool for liver cancer detection and image-guided surgery.
View Article and Find Full Text PDF

Hepatic ischemia/reperfusion (HI/R) presents significant challenges in surgical liver transplantation and hepatic ischemic shock, with few effective clinical preventive measures available. This study explores the potential protective effects and underlying mechanisms of phosphocreatine (PCr) in the context of HI/R. We established an in vitro ischemia/reperfusion model using hepatocellular carcinoma HepG2 cells and normal liver L02 cells.

View Article and Find Full Text PDF
Article Synopsis
  • Cucurbitacin B (CuB) is a natural compound known for its strong anticancer effects, but its effectiveness is limited due to poor absorption in the body when taken orally.
  • Researchers studied how CuB is metabolized in rats after oral administration, identifying 13 metabolites, with one key variant, CuB-Cys, showing similar anti-cancer activity as CuB but with less toxicity toward normal cells.
  • The study sheds light on CuB's metabolic pathways and suggests that using its metabolites, like CuB-Cys, could enhance its therapeutic effects while minimizing side effects in cancer treatment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!